Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Man Group plc slashed its stake in Regeneron Pharmaceuticals by over 40%, unloading 24,377 shares in Q4. Despite this selloff, Regeneron’s stock climbed 3.2%, shrugging off investor jitters like a ...

Key Takeaways The S&P 500 slipped 0.4% on Tuesday, May 20, snapping a six-day winning streak as investors' confidence on ...